165 related articles for article (PubMed ID: 9616135)
1. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
Harker LA; Marzec UM; Novembre F; Sundell IB; Waller EK; Karpatkin S; McClure HM; Kelly AB; Stead RB
Blood; 1998 Jun; 91(12):4427-33. PubMed ID: 9616135
[TBL] [Abstract][Full Text] [Related]
2. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients.
Cole JL; Marzec UM; Gunthel CJ; Karpatkin S; Worford L; Sundell IB; Lennox JL; Nichol JL; Harker LA
Blood; 1998 May; 91(9):3239-46. PubMed ID: 9558379
[TBL] [Abstract][Full Text] [Related]
3. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
5. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
6. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
7. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
[TBL] [Abstract][Full Text] [Related]
8. Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model.
Nishiyama U; Kuwaki T; Akahori H; Kato T; Ikeda Y; Miyazaki H
J Thromb Haemost; 2005 Feb; 3(2):355-60. PubMed ID: 15670044
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression.
Sundell IB; Koka PS
Curr HIV Res; 2006 Jan; 4(1):107-16. PubMed ID: 16454716
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
11. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
12. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
Nomura S; Dan K; Hotta T; Fujimura K; Ikeda Y
Blood; 2002 Jul; 100(2):728-30. PubMed ID: 12091377
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
15. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
16. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.
Harker LA; Roskos LK; Marzec UM; Carter RA; Cherry JK; Sundell B; Cheung EN; Terry D; Sheridan W
Blood; 2000 Apr; 95(8):2514-22. PubMed ID: 10753829
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
[TBL] [Abstract][Full Text] [Related]
18. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
[TBL] [Abstract][Full Text] [Related]
19. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
